TSA for bleeding events and HIT.

A: Fixed-effect model of trial sequential analysis for bleeding events (regional citrate versus systemic heparin). A diversity adjusted information size of 4061 participants calculated on the basis of a risk of 15.06% in the heparin group, relative risk reduction (RRR) of 20%, α=5% (two sided), β=20%, and I²=0%. Full blue cumulative Z-curve crossed both the etched green conventional boundary and the full red trial sequential monitoring boundary. B: Fixed-effect model of trial sequential analysis for HIT events. A diversity adjusted information size of 13381 participants calculated on the basis of a risk of 5.06% in the heparin group, RRR of 20%, α=5% (two sided), β=20%, and I²=0%. Full blue cumulative Z-curve crossed the etched green conventional boundary but not the full red trial sequential monitoring boundary.